{
  "nctrialId": "HC-1796",
  "title": "A  Double-Blind, Placebo-Controlled  Study of HTN-295 (ACE inhibitor) in Patients With Type 2 Diabetes",
  "officialTitle": "A  Double-Blind, Placebo-Controlled  Study of HTN-295 (ACE inhibitor) in Patients With Type 2 Diabetes",
  "sponsor": "Princess Margaret Cancer Centre",
  "indication": "Type 2 Diabetes",
  "phase": "Phase 3",
  "fileName": "HC-1796.json",
  "fileSize": 340942,
  "date": "2023-07-29",
  "completionDate": "2027-04-03",
  "drugName": "HTN-295 (ACE inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a  double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of HTN-295 (ACE inhibitor) in patients with Type 2 Diabetes. The study will enroll approximately 349 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 22-59 years\n- Confirmed diagnosis of Type 2 Diabetes\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- HbA1c between 7.0% and 10.0%\n- Body mass index (BMI) between 25 and 40 kg/m\u00b2\n- On stable antidiabetic medication for \u22653 months\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- History of severe hypoglycemia within past 6 months\n- Estimated GFR <45 mL/min/1.73m\u00b2\n- History of diabetic ketoacidosis",
  "csr_id": "HC-1796"
}